Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial

Multiple myeloma (MM) patients typically receive several lines of combination therapy and first-line treatment commonly includes lenalidomide. As patients age, they become less tolerant to treatment, requiring convenient/tolerable/lenalidomide-free options. Carfilzomib and/or bortezomib-exposed/into...

Descripción completa

Detalles Bibliográficos
Autores principales: Dimopoulos, Meletios A., Schjesvold, Fredrik, Doronin, Vadim, Vinogradova, Olga, Quach, Hang, Leleu, Xavier, Montes, Yolanda Gonzalez, Ramasamy, Karthik, Pompa, Alessandra, Levin, Mark-David, Lee, Cindy, Mellqvist, Ulf Henrik, Fenk, Roland, Demarquette, Hélène, Sati, Hamdi, Vorog, Alexander, Labotka, Richard, Du, Jichang, Darif, Mohamed, Kumar, Shaji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786921/
https://www.ncbi.nlm.nih.gov/pubmed/35075109
http://dx.doi.org/10.1038/s41408-021-00593-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786921/
https://www.ncbi.nlm.nih.gov/pubmed/35075109
http://dx.doi.org/10.1038/s41408-021-00593-2

Ejemplares similares